Federal Register: HHS Notices · October 6, 2026 · Primary source
Determination PRALIDOXIME CHLORIDE (Autoinjector) (Pralidoxime Chloride) Solution, 600 Milligrams/2 Milliliters (300 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Read the full document at Federal Register: HHS Notices.
What this may mean
Procedural; limited direct operational impact. Drug-product pathway determination affecting manufacturers and supply chain; no provider or payor operational change.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- Federal Register: HHS Notices · October 6, 2026Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for InformationScore 87
- Federal Register: HHS Notices · October 21, 2026No Adjustment to HHS Civil Monetary Penalty Amounts for 2026Score 60
- Federal Register: HHS Notices · October 2, 2026Patient Safety Organizations: Delisting for Cause for the Hospital Rep Safety Solutions Corp. PSOScore 35
- Federal Register: HHS Notices · October 23, 2026HHS Approval of Entities That Certify Medical Review OfficersScore 30
- Federal Register: HHS Notices · October 20, 2026New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry; AvailabilityScore 30
- Federal Register: HHS Notices · October 1, 2026Period for Refugee Cash Assistance and Refugee Medical Assistance; CorrectionScore 30